Qiagen NV (XTER:QIA) Piotroski F-Score: 7 (As of Jun. 30, 2026) — 17% Above Median


XTER:QIA Qiagen NV XTER:QIA
71 GF Score
Price €34.57
GF Value €45.90
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Qiagen NV Piotroski F-Score?

Qiagen NV XTER:QIA +0.74% 71 Piotroski F-Score is 7 as of Jun. 30, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates XTER:QIA with a GF Score™ of 71/100 and a GF Value™ of €45.90 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Qiagen NV ranks better than 94.29% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Qiagen NV has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Qiagen NV's Piotroski F-Score or its related term are showing as below:

XTER:QIA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Qiagen NV was 8. The lowest was 3. And the median was 6.

Qiagen NV  (XTER:QIA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Qiagen NV Piotroski F-Score Related Terms


Qiagen NV Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Qiagen NV's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Piotroski F-Score Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 4.00 5.00 8.00

Qiagen NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 7.00 7.00 8.00 7.00

XTER:QIA vs TWST, CRL, BLLN: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Piotroski F-Score falls into.


XTER:QIA
71GF Score
Qiagen NV XTER:QIA
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 83.449 + 110.797 + 92.086 + 58.857 = €345 Mil.
Cash Flow from Operations was 139.964 + 140.596 + 160.665 + 87.044 = €528 Mil.
Revenue was 462.579 + 453.761 + 461.519 + 425.857 = €1,804 Mil.
Gross Profit was 289.826 + 282.233 + 277.78 + 267.807 = €1,118 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(5129.466 + 5049.198 + 5583.579 + 5364.172 + 5001.486) / 5 = €5225.5802 Mil.
Total Assets at the begining of this year (Mar25) was €5,129 Mil.
Long-Term Debt & Capital Lease Obligation was €1,424 Mil.
Total Current Assets was €1,332 Mil.
Total Current Liabilities was €414 Mil.
Net Income was -170.434 + 88.348 + 84.348 + 83.951 = €86 Mil.

Revenue was 461.106 + 452.184 + 497.748 + 447.197 = €1,858 Mil.
Gross Profit was 32.296 + 277.785 + 318.292 + 285.53 = €914 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(5341.455 + 5188.131 + 5649.447 + 5433.589 + 5129.466) / 5 = €5348.4176 Mil.
Total Assets at the begining of last year (Mar24) was €5,341 Mil.
Long-Term Debt & Capital Lease Obligation was €1,251 Mil.
Total Current Assets was €1,612 Mil.
Total Current Liabilities was €478 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Qiagen NV's current Net Income (TTM) was 345. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Qiagen NV's current Cash Flow from Operations (TTM) was 528. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=345.189/5129.466
=0.06729531

ROA (Last Year)=Net Income/Total Assets (Mar24)
=86.213/5341.455
=0.01614036

Qiagen NV's return on assets of this year was 0.06729531. Qiagen NV's return on assets of last year was 0.01614036. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Qiagen NV's current Net Income (TTM) was 345. Qiagen NV's current Cash Flow from Operations (TTM) was 528. ==> 528 > 345 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1424.272/5225.5802
=0.27255768

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1251.198/5348.4176
=0.23393798

Qiagen NV's gearing of this year was 0.27255768. Qiagen NV's gearing of last year was 0.23393798. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1332.32/414.43
=3.21482518

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1612.156/478.173
=3.37149107

Qiagen NV's current ratio of this year was 3.21482518. Qiagen NV's current ratio of last year was 3.37149107. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Qiagen NV's number of shares in issue this year was 208.939. Qiagen NV's number of shares in issue last year was 220.189. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1117.646/1803.716
=0.61963524

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=913.903/1858.235
=0.49181239

Qiagen NV's gross margin of this year was 0.61963524. Qiagen NV's gross margin of last year was 0.49181239. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1803.716/5129.466
=0.35163816

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1858.235/5341.455
=0.34788929

Qiagen NV's asset turnover of this year was 0.35163816. Qiagen NV's asset turnover of last year was 0.34788929. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Qiagen NV has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Qiagen NV (XTER:QIA) has a Piotroski F-Score of 7 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Qiagen NV and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Qiagen NV's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Qiagen NV ranks #12 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 5.7%.
Is Qiagen NV's Piotroski F-Score too high?
Qiagen NV's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Qiagen NV's value of 7 is 40% above this industry median. Based on the distribution chart, Qiagen NV ranks #12 out of 210 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Piotroski F-Score compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #12 out of 210 companies for Piotroski F-Score. This places Qiagen NV in the top 6% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Qiagen NV's value of 7 is 40% above this benchmark. Historically, Qiagen NV's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Qiagen NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Qiagen NV and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.90, compared to a current price of €34.57 — trading 24.7% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Medical Diagnostics & Research industry median of 5.00. Qiagen NV's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Piotroski F-Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (XTER:QIA) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €34.57 is trading 24.7% below its estimated GF Value™ of €45.90. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for XTER:QIA:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: €45.90 vs. price of €34.57 (24.7% below fair value)
  • GF Score™: 71/100 with 2 warning signs
  • Industry Position: 40% above the Medical Diagnostics & Research median (#12 of 210)

No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
71GF Score

Get the complete analysis for XTER:QIA

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.57
Price
€45.90
GF Value